Bronchodilators form the foundation of symptomatic treatment of COPD. Several long-acting
bronchodilators are now available for use in COPD, but publications of large-scale studies of …

Chronic obstructive pulmonary disease (COPD) is an under-recognized cause of morbidity
and mortality worldwide that imposes an ever increasing burden on the patient and society …

BACKGROUND: The recommended treatment of COPD exacerbations includes
administration of short-acting bronchodilators that act to reverse bronchoconstriction, restore …

Small airway changes precede impairment in forced expiratory volume in 1 s (FEV1) in early
chronic obstructive pulmonary disease (COPD), with significant loss of terminal bronchioles …

Chronic obstructive pulmonary disease (COPD), which is estimated to affect 32 million
Americans, is the fifth leading cause of death in the United States. This retrospective study …

Background Recent studies report a lower mortality rate during treatment with long-acting
muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) …

Background While inhaled bronchodilators reduce symptoms and acute exacerbations of
chronic obstructive pulmonary disease (COPD), their use is associated with increased …

Background Although the efficacy of inhaled long-acting bronchodilators has been well
documented in randomised controlled studies, whether similar effects are obtained in real …

Background Bronchodilators are first-line therapy for COPD. There is some evidence that
they may increase the risk of cardiac arrhythmias. Methods We used the computerized …

Patients with COPD may respond differently to anticholinergic and beta-agonist
bronchodilators. Previously, in acutely ill COPD patients, we showed similar improvements …